ong-term outcome study of patients with refractory nephrotic syndrome after multicenter, double blind, randomized, placebo-controlled trial of rituximab
Not Applicable
- Conditions
- refractory nephrotic syndrome
- Registration Number
- JPRN-UMIN000015220
- Lead Sponsor
- on-Profit Organization Japan Clincal Research Support Unit
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 58
Inclusion Criteria
Not provided
Exclusion Criteria
Patients who did not participate in the trial
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method First relapse after rituximab treatment
- Secondary Outcome Measures
Name Time Method 1. Administration of immunosuppressive agents after rituximab treatment 2. Re-treatment of rituximab 3. Late onset adverse events after rituximab treatment